Friday, 19 Jan 2018

You are here

Top 16 Drugs in Rheumatology 2016

Using data compiled from annual reports, SEC filings, press releases, company websites, recently released sales figures show that in 2016, 11 of the top 16 rheumatology drugs demonstrated blockbuster sales (>$1 billion per annum).  Highlights from this report include:

  • TNF inhibitors – the big three TNFi (ADA, ETN, INF) lead the way with $33.7 billion in 2016.  Humira continued as the worldwide leader in sales $16.1 billion.  Sales of all 5 TNFi totaled $37.9 billion.  While Humira growth (15%) continues, Enbrel has flattened (2%) and Remicade has declined (-2%).
  • Greatest growth from 2015 to 2016 was Cosentyx (332% to $1.1 billion in 2016), Otezla (116% to $1 billion) and Xeljanz (77% to $927 million).
  • Greatest losses were seen for NSAID market, with -12% drop for Celebrex, -4% drop for Arcoxia (Cox-2 inhibitor sold outside the USA) and a -2% drop for aspirin.
  • Psoriatic arthritis therapeutic market was hot with substantial growth by Cosentyx (332%), Otezla (116%) and Stelara (31%), in addition to TNF inhibitor growth.

TOP 16 RHEUMATOLOGY DRUGS – 2016 SALES

 

Brand

Generic

2015 Sales*

2016 Sales*

Growth Rate

1

Humira

Adalimumab

14012

16078

15%

2

Enbrel

Etanercept

8697

8874

2%

3

Remicade

Infliximab

8791

8789

-2%

4

Rituxan

Rituximab

5584

5765

3%

5

Stelara

Ustekinumab

2474

3232

31%

6

Simponi

Golimumab

2133

2719

27%

7

Orencia

Abatacept

1957

.2368

21%

8

Actemra

Tocilizumab

1432

1697

19%

9

Cimzia

Certolizumab

1191

1438

21%

10

Cosentyx

Secukinumab

261

1128

332%

11

Otezla

Apremilast

472

1017

116%

12

Xeljanz

Tofacitinib

523

927

77%

13

Celebrex

Celcoxib

830

733

-12%

14

Aspirin

Aspirin

525

513

-2%

15

Arcoxia

Etoricoxib

471

450

-4%

16

Ilaris

Canakinumab

236

283

20%

* Worldwide sales expressed millions (USD)

Add new comment

More Like This

Laparoscopic Gastric Sleeve Compared to Bypass Bariatric Surgery

JAMA reports the results of a 5 year Finnish study comparing the results of laparoscopic sleeve gastrectomy vs Roux-en-Y gastric bypass and shows that gastric bypass yielded greater weight loss at 5 years, the difference was not statistically significant, in patients with morbid obesity. 

2018 Predictions for Rheumatology

MedPage Today Editors surveyed a few rheumatologists for their major news predictions in 2018. Read on for predictions regarding drug pricing, biosimilars, autoimmunity and checkpoint inhibitors, and thrombotic events and JAK inhibition.

PRECISION Subanalyses Question Aspirin Use

The PRECISION trial reported last year that celecoxib appears to be safer than the NSAIDs naproxen or ibuprofen in treating osteoarthritis (OA) and rheumatoid arthritis patients who are at increased cardiovascular risk. New data suggests that adding aspirin may nullify this advantage, according to a study presented at the annual American Heart Association meeting and reported by Medscape.

Physician Visit Times Vary Worldwide

A metanalysis published in BMJ Open shows that for half of the world’s population, primary care doctor visits last less than five minutes and that the range is from 48 seconds in Bangladesh to 22.5 minutes in Sweden (US PCP visit averages at 20 minutes).

Surgical Decompression Ineffective for Subacromial Shoulder Pain

Lancet reports that a common surgical intervention, arthroscopic sub-acromial decompression is ineffective compared to arthroscopy or no surgery at all.